Form 4: Soleno Therapeutics Merger: Insider Transactions Detailed

SEC Form 4 filing reveals insider transactions for Soleno Therapeutics Inc. (SLNO) related to its merger with Neocrine Biosciences, Inc.

Summary

• This filing is a Form 4, reporting changes in beneficial ownership of securities.
• It details transactions by Patricia C. Hirano, Senior Vice President, Regulatory Affairs at Soleno Therapeutics Inc.
• The transactions occurred on May 18, 2026, in connection with the merger between Soleno Therapeutics, Inc. and Neocrine Biosciences, Inc.
• Common stock, restricted stock units (RSUs), employee stock options, and warrants were involved.
• All outstanding shares, vested and unvested RSUs, options, and warrants were cancelled and converted into the right to receive cash consideration of $53.00 per share.
• Patricia C. Hirano's beneficial ownership of common stock is reported as 22,702 shares, directly owned.
• Several employee stock options with varying exercise prices were cancelled and converted into cash payments.
• A warrant with an exercise price of $4.50 was also cancelled and converted into a cash payment.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it reports on completed transactions related to a merger and cash-out, rather than ongoing operational performance or future strategic initiatives.

Positives

• The merger with Neocrine Biosciences, Inc. provides a cash payout of $53.00 per share for all outstanding common stock, vested and unvested RSUs.
• Insider stock options and warrants were also converted into cash payments, reflecting value realization for these instruments.

Negatives

• All outstanding equity awards (options and warrants) were cancelled as part of the merger, meaning no future equity participation in the combined entity for these awards.
• The filing indicates a complete conversion to cash, suggesting no ongoing equity stake for the reporting person in the surviving entity through these specific instruments.

Risks

• The primary risk highlighted is the cancellation of all equity awards (options and warrants) in exchange for cash, which means holders will not participate in any future upside of the combined company.
• The merger itself carries inherent risks associated with integration and achieving the strategic goals of the combined entity, though these are not detailed in this specific filing.

Future Outlook

The filing does not contain forward-looking statements or guidance. It reports on completed transactions related to a merger.

Management Comments

• Patricia C. Hirano, Senior Vice President, Regulatory Affairs, is the reporting person.
• The filing is signed by Anish Bhatnagar, Attorney-in-Fact, for Patricia C. Hirano.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard for reporting insider transactions, particularly during significant corporate events like mergers. The cash-out structure is typical in acquisition scenarios where the target company ceases to exist as an independent entity.

Stakeholder Impact

• Shareholders: All common stockholders received $53.00 in cash per share.
• RSU Holders: Holders of vested and unvested RSUs received $53.00 in cash per share.
• Option Holders: Holders of employee stock options received cash payments based on the difference between the merger consideration and their exercise price.
• Warrant Holders: Holders of warrants received cash payments based on the merger consideration minus the exercise price.
• Employees: Employees holding options or RSUs have had these awards converted to cash, impacting their potential future equity participation.

Next Steps

• The merger between Soleno Therapeutics, Inc. and Neocrine Biosciences, Inc. has been completed.
• Shareholders and holders of equity awards have received cash consideration.

Key Dates

Keywords

SEC Form 4, Soleno Therapeutics, SLNO, Insider Transaction, Merger, Neocrine Biosciences, Patricia C. Hirano, Stock Options, Warrants, RSUs, Beneficial Ownership, Regulatory Affairs